State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, China.
Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
EBioMedicine. 2022 Apr;78:103943. doi: 10.1016/j.ebiom.2022.103943. Epub 2022 Mar 18.
Tigecycline is one of the few last-resort antibiotics for the treatment of carbapenem-resistant Enterobacteriaceae infection, the incidence of which has been rapidly increasing. However, the emergence and spread of tigecycline resistance genes tet(X) (including tet(X3) and tet(X4)) has largely compromised the efficient usage of tetracyclines in the clinical settings.
The synergistic effect was determined by a checkerboard minimum inhibitory concentration (MIC) assay, a time-killing assay and scanning electron microscopy (SEM) analysis. In-depth mechanisms were defined using an enzyme inhibition assay, western blotting, RT-PCR analysis, molecular dynamics (MD) simulations, biolayer interferometry (BLI) assay and metabolomics analysis.
Herein, our work identified a natural compound, plumbagin, as an effective broad-spectrum inhibitor of Tet(X) (also known as monooxygenase) by simultaneously inhibiting the activity and the production of Tet(X3)/Tet(X4). Plumbagin in combination with tetracyclines showed a synergistic bactericidal effect against Tet(X3)/Tet(X4)-producing bacteria. Mechanistic studies revealed that direct engagement of plumbagin with the catalytic pocket of Tet(X3)/Tet(X4) induced an alternation in its secondary structure to inhibit the activity of these monooxygenases. As a consequence, monotherapy or combination therapy with plumbagin increases the oxidative stress and metabolism in bacteria. Moreover, in a mouse systemic infection model of tet(X4)-positive E. coli, the combination of plumbagin and methacycline exhibited remarkable treatment benefits, as shown by a reduced bacterial load and the alleviation of pathological injury.
Plumbagin, as an inhibitor of Tet(X3)/Tet(X4), represents a promising lead drug, as well as an adjunct with tetracyclines to treat bacterial infections, especially for extensively drug-resistant bacteria harbouring Tet(X3)/Tet(X4).
The National Natural Science Foundation of China.
替加环素是治疗碳青霉烯类耐药肠杆菌科感染的少数最后手段抗生素之一,其发病率一直在迅速上升。然而,替加环素耐药基因 tet(X)(包括 tet(X3)和 tet(X4))的出现和传播在很大程度上影响了四环素在临床环境中的有效使用。
通过棋盘微量稀释法(MIC)测定、时间杀伤试验和扫描电子显微镜(SEM)分析来确定协同作用。通过酶抑制试验、western blot 分析、RT-PCR 分析、分子动力学(MD)模拟、生物层干涉(BLI)试验和代谢组学分析来确定深入的机制。
在此,我们的工作发现了一种天然化合物,即白花丹醌,通过同时抑制 Tet(X)(也称为单加氧酶)的活性和产生,是 Tet(X3)/Tet(X4)的有效广谱抑制剂。白花丹醌与四环素联合使用对产生 Tet(X3)/Tet(X4)的细菌具有协同杀菌作用。机制研究表明,白花丹醌与 Tet(X3)/Tet(X4)的催化口袋直接结合,诱导其二级结构改变,从而抑制这些单加氧酶的活性。因此,单独或联合使用白花丹醌可增加细菌的氧化应激和代谢。此外,在 tet(X4)阳性大肠杆菌的小鼠全身感染模型中,白花丹醌和米诺环素联合治疗表现出显著的治疗益处,表现为细菌载量减少和病理损伤减轻。
作为 Tet(X3)/Tet(X4)的抑制剂,白花丹醌代表了一种有前途的先导药物,以及一种与四环素联合治疗细菌感染的药物,特别是对携带 Tet(X3)/Tet(X4)的广泛耐药细菌。
国家自然科学基金。